Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.

摘要: Many reports have demonstrated that thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) are biomarkers for the response prognosis of patients treated with 5-fluorouracil (5-FU)-based chemotherapy. A newly developed orally administered drug, fluoropyrimidine (S-1), has been clinical efficacy when combined an inhibitor DPD. In this study, relationship between immunoreactivity to TS DPD in biopsy specimens effects chemotherapy was investigated 41 S-1 therapy advanced gastric cancer. Response rates were 54% (13/24) TS(+) 53% (9/17) TS(-) (p=0.938), those DPD(+) (-) 61% (11/18) 48% (11/23) (p=0.397), respectively. The median survival time all subjects 253 days. There no significant difference (284 days) (189 days: p=0.670). 18 had times slightly longer (338 than 23 DPD(-) (207 p=0.206). This study indicates may be effective treatment cancer patients, regardless intratumoral status. Further studies needed confirm these results larger numbers patients.